IMMUNIC IMUX 深 沪
等待开盘 09-13 09:30:00 美东时间
0.7943
-0.058
-6.77%
华盛通- 最 高0.888
- 今 开0.8706
- 成交量 227.16万股
- 最 低 0.783
- 昨 收 0.852
- 总市值 7610.78万
- 52周最高 1.8883
- 市盈率 静 --
- 换手率 2.37%
- 52周最低 0.561
- 委 比 93.67%
- 总股本 9581.75万
- 历史最高 28.99
- 量 比 1.58
- 振 幅 12.32%
- 历史最低 0.561
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunic Secures New US Patent Protection for Multiple Sclerosis Drug Vidofludimus Calcium Through 2041
Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that
09-09 18:32
Analysts’ Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-12 18:20
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $10 price target.
08-08 20:33
Immunic Advances Phase 3 Trials and Financial Health
Immunic ( ($IMUX) ) just unveiled an announcement. Immunic, Inc. announced sign...
08-07 18:56
Immunic Q2 EPS $(0.20) Misses $(0.17) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same
08-07 18:37
Immunic Reports 92% of MS Patients Had No Disability Worsening After 3 Years on Lead Oral Drug
Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new
06-24 18:36
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $10 price target.
06-05 19:44
Immunic Completes Enrollment For Both Phase 3 ENSURE Trials Of Vidofludimus Calcium In Relapsing Multiple Sclerosis; Top-Line Data Expected End Of 2026
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –– Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple
06-05 18:33
快讯 | Immunic Inc：Leerink Partners将目标价从6美元削减至4美元
Immunic Inc : Leerink Partners Cuts Target Price to $4 From $6
06-03 18:03
